Meeting Banner
Abstract #0783

Final Results of IMAPS: An International Multi-Centre Assessment of Prostate MR Spectroscopy.

Tom WJ Scheenen1, Jurgen J. Ftterer1, Elisabeth Weiland2, Paul van Hecke3, Marc Lemort4, Christian M. Zechmann5, Heinz-Peter Schlemmer6, Dale R. Broome7, Geert M. Villeirs8, Jaoping Lu9, Jelle O. Barentsz1, Stefan O. Roell2, Arend Heerschap1

1Radiology (667), Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 2Siemens Healthcare; 3University Hospital, Katholieke Universiteit Leuven, Belgium; 4the Bordet Institute, Belgium; 5German Cancer Research Center DKFZ, Germany; 6University of Tuebingen, Germany; 7Loma Linda University Medical Centre, USA; 8Ghent University Hospital, Belgium; 9Shanghai Changhai Hospital, China

IMAPS is a multi-centre study evaluating the use of 3D 1H-spectroscopic imaging of the prostate to detect and localize prostate cancer. 99 patients and were contributed by 8 different institutions. With histopathology of resected prostates as a reference, we evaluated the (choline+creatine)/citrate integral ratio of selected voxels in different anatomical regions and tumor tissue. The (choline+creatine)/citrate ratio is significantly different for the peripheral zone, the central gland and cancer tissue of patients with prostate cancer. Moreover, no significant differences were found in non-cancer tissues for patients from different contributing institutions.